“In such a volatile market, it is quite difficult to find reasonably safe and high-growth biotech stocks,” acknowledges the author of today’s article. Of course, while it may be difficult, it’s not impossible – and they proceed to highlight two biotech stocks that appear to fit the bill: a “rare gem” focused on rare and ultra-rare diseases and a neuropsychiatric disorder specialist, “both poised for an upward trajectory in the coming months.” For more on these two underrated biotech stocks, CLICK HERE.